Primary	O
hyperparathyroidism	O
and	O
the	O
heart	B-Organ
:	O
cardiac	B-Organ
abnormalities	O
correlated	O
to	O
clinical	O
and	O
biochemical	O
data	O
.	O

Comparing	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHP	O
)	O
to	O
a	O
normocalcemic	O
control	O
population	O
,	O
those	O
with	O
PHP	O
have	O
a	O
higher	O
incidence	O
of	O
cardiovascular	B-Anatomical_system
disease	O
and	O
cardiac	B-Organ
abnormalities	O
.	O

This	O
study	O
aimed	O
at	O
correlating	O
cardiac	B-Organ
findings	O
(	O
valvular	B-Multi-tissue_structure
and	O
myocardial	B-Multi-tissue_structure
calcification	O
,	O
myocardial	B-Multi-tissue_structure
hypertrophy	O
)	O
with	O
clinical	O
data	O
(	O
age	O
,	O
sex	O
,	O
clinical	O
manifestation	O
,	O
nephrolithiasis	O
,	O
nephrocalcinosis	O
,	O
hypertension	O
,	O
skeletal	B-Anatomical_system
abnormalities	O
,	O
hypercalcemic	O
syndrome	O
)	O
and	O
biochemical	O
data	O
(	O
serum	B-Organism_substance
calcium	O
,	O
serum	B-Organism_substance
phosphate	O
,	O
serum	B-Organism_substance
iPTH	O
level	O
,	O
serum	B-Organism_substance
creatinine	O
)	O
.	O

A	O
group	O
of	O
132	O
consecutive	O
patients	O
with	O
surgically	O
verified	O
PHP	O
(	O
94	O
women	O
,	O
38	O
men	O
;	O
ages	O
15	O
-	O
86	O
,	O
mean	O
age	O
57	O
+	O
/	O
-	O
16	O
years	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Blood	B-Organism_substance
chemistry	O
,	O
clinical	O
presentation	O
,	O
radiography	O
,	O
and	O
echocardiography	O
were	O
carried	O
out	O
in	O
all	O
patients	O
for	O
univariate	O
and	O
multivariate	O
analyses	O
of	O
all	O
parameters	O
.	O

There	O
was	O
no	O
statistical	O
correlation	O
between	O
clinical	O
symptoms	O
,	O
biochemical	O
data	O
,	O
and	O
cardiac	B-Organ
calcific	O
alterations	O
.	O

Typical	O
skeletal	B-Anatomical_system
manifestations	O
(	O
osteolysis	O
/	O
subperiostal	O
resorption	O
)	O
and	O
valvular	B-Multi-tissue_structure
calcifications	O
were	O
significantly	O
correlated	O
to	O
left	B-Multi-tissue_structure
ventricular	I-Multi-tissue_structure
hypertrophy	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

Cardiac	B-Organ
abnormalities	O
such	O
as	O
calcific	O
myocardial	B-Multi-tissue_structure
deposits	O
or	O
mitral	B-Multi-tissue_structure
and	O
aortic	B-Multi-tissue_structure
valvular	I-Multi-tissue_structure
calcifications	O
do	O
not	O
correlate	O
with	O
laboratory	O
findings	O
and	O
clinical	O
presentation	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

There	O
was	O
no	O
biochemical	O
or	O
clinical	O
variable	O
that	O
could	O
predict	O
the	O
frequency	O
or	O
severity	O
of	O
valvular	B-Multi-tissue_structure
sclerosis	O
or	O
calcific	O
deposits	O
in	O
the	O
myocardium	B-Multi-tissue_structure
.	O

However	O
,	O
PHP	O
-	O
related	O
skeletal	B-Anatomical_system
abnormalities	O
and	O
valvular	B-Multi-tissue_structure
calcification	O
were	O
predicting	O
factors	O
for	O
left	B-Multi-tissue_structure
ventricular	I-Multi-tissue_structure
hypertrophy	O
,	O
a	O
reversible	O
cardiac	B-Organ
manifestation	O
of	O
PHP	O
.	O

Myocardial	B-Multi-tissue_structure
hypertrophy	O
is	O
more	O
often	O
found	O
with	O
classic	O
symptomatic	O
PHP	O
with	O
osseous	B-Organ
abnormalities	O
.	O

